Roivant Sciences (ROIV) EBITDA Margin (2020 - 2025)
Roivant Sciences (ROIV) reported EBITDA Margin of 16966.13% for Q4 2025, down 1392354.0% on a YoY basis from N/an in Q4 2024, and up 12.96% quarter-over-quarter from 19492.87% in Q3 2025.
Roivant Sciences (ROIV) EBITDA Margin (2020 - 2025) Analysis & Trends
Roivant Sciences has reported EBITDA Margin for 6 years, with the latest figure at 16966.13% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 1392354.0% year-over-year to 16966.13%; the trailing twelve-month figure through Dec 2025 stood at 8162.96% (down 2006504.0% YoY), and the FY2026 full-year result was 6235.69%, down 278237.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 16966.13%, up from 19492.87% in the prior quarter.
- The five-year high for EBITDA Margin was 32948.56% in Q4 2023, with the low at 19492.87% in Q3 2025.
- Historically, EBITDA Margin has averaged 3642.27% across 5 years, with a median of 3042.59% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 3516576 bps — and 2024, when it plunged 3599115 bps.
- Roivant Sciences' EBITDA Margin stood at 1010.73% in 2021, then slumped by 119 bps to 2217.2% in 2022, then surged by 1586 bps to 32948.56% in 2023, then slumped by 109 bps to 3042.59% in 2024, then sank by 458 bps to 16966.13% in 2025.
- The last three EBITDA Margin figures came in at 16966.13% (Q4 2025), 19492.87% (Q3 2025), and 13130.05% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16,966.13% |
| Sep 30, 2025 | -19,492.87% |
| Jun 30, 2025 | -13,130.05% |
| Dec 31, 2024 | -3,042.59% |
| Sep 30, 2024 | -7,636.04% |
| Jun 30, 2024 | -1,279.54% |
| Dec 31, 2023 | 32,948.56% |
| Sep 30, 2023 | -5,863.24% |
| Jun 30, 2023 | -1,278.27% |
| Dec 31, 2022 | -2,217.20% |
| Sep 30, 2022 | -2,240.21% |
| Jun 30, 2022 | -6,536.44% |
| Dec 31, 2021 | -1,010.73% |
| Sep 30, 2021 | -4,893.32% |
| Jun 30, 2021 | -1,995.95% |
| Dec 31, 2020 | -4,505.57% |
| Sep 30, 2020 | -11,832.28% |
| Jun 30, 2020 | -7,262.25% |